Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release